During the epidemic, doctors, pharmacists, and virologists scrambled to make sense of the enigmatic new coronavirus and its mutant forms. There was no recognised treatment for SARS-CoV-2 at the time. To ensure a reliable supply, governments fought one another to acquire hydroxychloroquine. Using cognitive technologies like ML and advanced analytics, pharmacovigilance automation is reshaping time-consuming manual tasks like data compilation and acquiring information for regulatory approval.

It led to skyrocketing sales of Antibiotic medicines. Since the drug's effectiveness in treating COVID was still unknown, the current disarray was cause for alarm.

The chaos surrounding the drug's efficacy in treating COVID is unknown. Clinical results of patients with severe COVID-19 are not improved by adding azithromycin to the standard of care, as was recently revealed through a consolidated, web-based, and automated gateway of randomised evaluations.

When it comes to pharmacovigilance, what exactly are artificial intelligence and automation? Cognitive technologies like machine learning (ML) and sophisticated analytics are being applied to the field of pharmacovigilance to automate the transformation of traditional data compilation processes and information collection for regulatory approval. Innovations in PV technology are based on the models that aim to enhance the risk-benefit assessment of drugs, facilitate the selection of the most effective therapies, and boost patient safety through product quality.

The Value of Robotics in Pharmacovigilance

Increase in employee productivity

The business case on automation in pharmacovigilance has its epicentre around process efficiency, with a more significant benefit being zero benefits when it comes to free resources. Automating pharmacovigilance frees up resources that can monitor and assess adverse drug responses, analyse real-world evidence, and investigate signals. Automating drug safety processes also results in lower PV costs, greater precision and consistency in testing cycles, and fewer errors. According to McKinsey research from 2020, you can realise automation's monetary worth to businesses. It is possible to understand the financial benefit of automating as much as 70% of PV-related work in just three years.

One can expedite overall case procedures and lessen the administrative burden on staff caused by repetitive tasks like duplicate case searches and reporting by enabling robotic intelligence for case automation. Historically, there has been a lack of more effective therapies for coronavirus sickness, so people have turned to over-the-counter antiviral drugs like azithromycin to alleviate their symptoms. This is because it eliminates the element of human mistake or misuse.

Robotic Process Automation technology also has several privacy and security advantages. From the simplest of jobs, like creating an automatic response, to the most complicated actions involving hundreds of bots, robotic process automation has the potential to be used to any process carried out by a corporation.

Accounting, payroll, inter-company reconciliation, bank reconciliation, and tax reporting are all administrative and financial responsibilities.

Management of procurement data, supplier relationships, and contracts Expense analysis and report management Procurement data supplier relationships and contracts

Information Technology: Keeping an Eye on Application Servers, Help Desks, and Tests Inventory management, analytics, and data management all fall under the purview of the supply chain. 

Time and attendance validation, employee master data management, and expense report tracking all fall under the purview of human resources. Using RPA, for instance, sensitive clinical cases of ICSR detection can get archived without human intervention.

Case Intake in Pharmacovigilance

Most PV budgets for pharmaceutical and medical device companies allocate to case processing. Adding further complexity is the annual incremental growth in case quantities. Naturally, reducing the cost of processing cases is a top priority for many executives in the pharmaceutical industry. By automating, they can take advantage of economies of scale and reduce their per-case safety report costs (ICSR). Additionally, automated processes produce proofs of concept along the whole PV value chain.

Modifications to the Drug's Benefit-Risk Profile

Traditional approaches to weighing a medicine's pros and cons rely on signal detection. The pharmaceutical industry still uses traditional investigative models to monitor individual reports of adverse events, analyse databases, and identify intervention possibilities in clinical trials. Some results may point to a drug's improved safety profile or therapeutic effectiveness, while others may disclose unwanted consequences.

Automation and cutting-edge analytics provided by cognitive AI and automation technologies have enormous possibilities for altering the PV ecosystem. All life cycle participants of drug development have some responsibility for patient safety, so it's up to them to determine the direction the industry will take, whether through radical innovation or more gradual adjustments. The epidemic has therefore provided us with the most important lesson of all.